ATXA THERAPEUTICS

ATXA Therapeutics Limited is a spin-out company from University College Dublin whose primary focus is to advance clinical trials and to secure marketing authorization of novel therapies for the treatment of Pulmonary Arterial Hypertension (PAH), serving a previously unmet medical need by offering improved treatment options to the prescribing physician and new hope for the PAH patient. Founded by Professor Therese Kinsella, ATXA was incorporated in May 2015 and is the culmination of over 20 years... of extensive research and over €15m of grant funding and a proven track record in understanding of the biology and signalling of the human prostanoid receptors in the cardiovascular disease and oncology setting. Supported with funding from a number of technology and commercialization development grants from Enterprise Ireland and Science Foundation Ireland, ATXA has developed a series of novel, highly selective small molecule drugs, and has identified and validated their potential use in a number of target disease indications including thrombosis/cardiovascular, oncology, anti-inflammatory and, in particular, in PAH. The ATXA team has expertise in cardiovascular and cancer biology with technical expertise in platelet biology, cellular and molecular biology, protein biology, pathological and histopathological and immunohistochemical techniques, digital pathology and biostatistics. In addition, ATXA have experience in drug discovery and early development; lead generation; lead optimization; candidate selection; medicinal chemistry; preclinical pharmacokinetics; intellectual property management and commercialization. ATXA Therapeutics Ltd will advance the late-stage development of their novel therapies that display substantial improvements over the existing standard-of-care, addressing critical unmet medical needs for efficacious new therapies to treat PAH.More